Jun 7 2009
Karen Lusky, staff writer for CAP Today, provides an excellent summary of the potential need for monitoring clopidogrel (Plavix) antiplatelet therapy in “Getting personal about antiplatelet therapy” in the May 2009 issue. She discusses polymorphisms of the CYP2C19 metabolic pathway and their effect upon clopidogrel dosage and efficacy. She also discusses phenotypic assays for antiplatelet therapy such as platelet aggregometry and the Accumetrics VerifyNow. There is a strong indication we will be doing more antiplatelet drug monitoring in the future.
Comments (0)
Posts
No comments here.